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Neuroleptic malignant syndrome (NMS) is an uncommon but
potentially fatal adverse reaction to neuroleptic drugs,
including amisulpride [1,2]. NMS most commonly presents
with increased body temperature, muscular rigidity of a ‘lead
pipe’ nature, altered mental status and autonomic dysfunction.
Other extrapyramidal movement disorders such as tremor and
cogwheel phenomena are also frequently present. The
treatment of NMS includes discontinuation of contributing
drugs and supportive therapy, but specific treatment with
dantrolene, bromocriptine, nondepolarizing neuromuscular
paralysis and benzodiazepines, among other such agents, has
been reported only anecdotally. A recent analysis of published
case reports [3] evaluated the efficacy of dantrolene in NMS;
it found that dantrolene, given as monotherapy, might be
helpful in managing this syndrome if the premedication was a
neuroleptic monotherapy. We present video evidence of the
effectiveness of dantrolene in reducing muscular rigidity,
tremor and cogwheel phenomena in a patient with NMS.
Amisulpride therapy was initiated in a 79-year-old patient with
a schizoaffective disorder. After 10 days the patient became
somnolent with a high body temperature (40.3°C), diaphor-
esis, tachycardia, rigid skeletal muscles of a ‘lead pipe’
character, cogwheel phenomena and resting tremor (video
footage is available in Additional data file 1). Laboratory
results revealed creatine kinase to be 15.1 µkat/l and myo-
globin to be 8,654 µg/l, indicating rhabdomyolysis. Blood
urea nitrogen was 11.6 mmol/l and creatine was 139 µmol/l,
indicating renal failure that probably was caused by
dehydration. Procalcitonin was within normal limits, excluding
infection. A brain computed tomography scan and lumbar
puncture findings were normal. NMS caused by treatment
with amisulpride was suspected and it was discontinued.
External cooling with sponging and fanning was started.
Bromocriptine, a dopamine agonist, was introduced at a dose
of 5 mg every 8 hours through a nasogastric tube, but after
1 day there was no clinical improvement and so bromo-
criptine was withdrawn. Then, 60 mg (1 mg/kg) dantrolene
was administered intravenously over 5 min. Muscle rigidity,
cogwheel phenomena and tremor disappeared within 10 min
(video footage is available in Additional file 2), but they
gradually reappeared within an hour. The dantrolene infusion
was repeated three times within 12 hours and body
temperature gradually decreased to 37.5°C. Bromocriptine
therapy was continued two more days. The patient’s level of
consciousness improved and signs of NMS disappeared
during subsequent days.
The diagnosis of NMS in this patient is based on identifying
the characteristic clinical manifestations in association with a
typical history of therapy with amisulpride, which antagonizes
dopaminergic D2/D3 receptor subtypes. The patient also
developed renal failure, which may participate in amisulpride
accumulation because amisulpride is eliminated unchanged
in urine.
Dantrolene might be useful in managing skeletal muscle
rigidity because it relaxes skeletal muscles by inhibiting
release of calcium from the sarcoplasmic reticulum, thereby
reducing actin-myosin contractile activity. In the videos
presented  (Additional data files 1 and 2) the effect of
dantrolene on muscular rigidity of a ‘lead pipe’ nature,
cogwheel phenomena and tremor are clearly visible. However,
the usefulness of dantrolene in NMS remains questionable,
and this is but one of a number of anecdotal reports. Never-
theless, it offers an additional visual impression of the effective-
ness of dantrolene on rigidity and tremor caused by NMS.
To conclude, we speculate that prompt reduction in NMS-
associated muscular rigidity by dantrolene contributed to a
decrease in body temperature. Our reporting of this case was
approved by the Hospital Committee for Medical Ethics
(University Medical Centre Ljubljana).
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Additional files
The following Additional file(s) for this article are available
online:
Additional file 1
A video file showing rigid skeletal muscles of a ‘lead pipe’
nature, cogwheel phenomena and resting tremor in a patient
with NMS caused by amisulpride treatment.
http://ccforum.com/content/supplementary/cc5907-s1.mov
Additional file 2
A video file showing skeletal muscle hypotonia without
cogwheel phenomena and tremor after dantrolene treatment
in a patient with NMS caused by amisulpride treatment.
http://ccforum.com/content/supplementary/cc5907-s2.mov
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